Cellectis Presents Preclinical APOC3 Editing Data at ESGCT 2026
The company reported 70% in vivo editing of human APOC3 and a 76% triglyceride reduction after a single administration. The headline identifies the therapy as.HEAL-101.
Related stories
Middle East Insurance reports Q3 insurance revenue of 14.1 million dinars
M impact | EQUITY | Oct 29, 2026, 02:47 PM UTC
Middle East Insurance Reports Q3 After-Tax Profit of 181,389 Dinars
M impact | EQUITY | Oct 29, 2026, 02:47 PM UTC
Shell CFO Says Company Is Not Cautious About Increasing Dividend
L impact | EQUITY | Oct 29, 2026, 02:47 PM UTC
Apple shares rise 1.66% as analysts support new MacBook launch
Apple gained 1.66% on Thursday, while the Nasdaq Composite fell 1.24% and the S&P 500 declined 0.29%.
M impact | EQUITY | Oct 29, 2026, 02:46 PM UTC
Hyatt Swings to Q3 Profit, Guides for FY26; Shares Up
Hyatt reported a swing to profit in the third quarter despite a slight decline in revenue from the prior year. The report says shares were higher.
M impact | EQUITY | Oct 29, 2026, 02:46 PM UTC
Al-Nisr Al-Arabi Insurance Reports Q3 Revenue of 8.3 Million Dinars
M impact | EQUITY | Oct 29, 2026, 02:44 PM UTC